Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Irinotecan in Advanced Colorectal Cancer
NCT00030797Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Feb 2001
- Primary completion
- May 2002
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan, capecitabine in colorectal cancer (CRC), sponsored by Swiss Group for Clinical Cancer Research. Started Feb 2001; status: completed.
02
Drugs
irinotecancapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00030797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030797.